AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 231 min read$PHVS

Pharvaris rises after BofA upgrades to Buy (PHVS:NASDAQ)

Pharvaris (PHVS) shares rose 3% premarket after BofA upgraded the stock to Buy from Neutral, citing its oral HAE potential. The brokerage kept its $44 price target. Pharvaris announced in September its.

Original reporting
seekingalpha.com
Published Oct 23, 2026, 11:48 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 11:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$PHVS
Bullish
high confidence
Mentioned
$PHVS
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$PHVSBullishMed
01

Why it matters

The upgrade may attract short‑term buying, but without fresh product data the rally could be short‑lived.

02

Market read

Analyst upgrade triggers modest pre‑market price gain; relevance primarily for traders focused on small‑cap biotech.

03

What to watch

No new clinical data disclosed; price move driven solely by analyst opinion.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Pharvaris N.V. is a Swiss biotech listed on NASDAQ; recent oral HAE therapy potential cited by BofA.

Company-level read

Ticker impact

$PHVSBullishHigh confidence
Context

BofA upgraded Pharvaris to Buy from Neutral, maintaining a $44 price target; stock rose >3% premarket.

Expected impact

upward pressure as traders price in the upgrade

Evidence & confidence

Analyst upgrade with a maintained target signals confidence in near‑term upside.

Market effects

Sector

May lift sentiment for other small‑cap biotech firms awaiting analyst coverage.

Regional

Limited to U.S. pre‑market trading; negligible broader regional effect.

Global

Low global relevance beyond niche biotech investors.

Counterpoint

What could challenge this read

Upgrade could be premature if upcoming trial data disappoints.

Key entities

  • Analyst
    Bank of America

    Upgraded PHVS to Buy, citing oral HAE potential.

Read at source← All news

StoryBank of America upgrades Pharvaris to Buy with $44 price target

Related articles

OCT 8
$PHVSMedAI 8/10

Pharvaris HAE drug shows faster symptom relief in Lancet study

Pharvaris' phase 3 study of deucrictibant IR for HAE attacks, published in The Lancet, met all endpoints, showing faster symptom relief and resolution than placebo. The drug was well-tolerated. FDA and EMA reviews are ongoing with decisions expected in 2027. According to the company, the study results support the drug's efficacy and safety.

investing.com5 min
OCT 8
$PHVSMedAI 8/10

Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet

Pharvaris (PHVS) announced positive results from the RAPIDe-3 study of deucrictibant IR for treating HAE attacks, published in The Lancet. The treatment showed rapid symptom relief and resolution, with a well-tolerated safety profile. The company's NDA and MAA for deucrictibant IR are under regulatory review, with a PDUFA target date of April 23, 2027.

globenewswire.com5 min
OCT 6
$PHVSMedAI 8/10

Pharvaris stock reiterated Buy at H.C. Wainwright on HAE therapy potential

H.C. Wainwright reiterated a Buy rating and $60 price target on Pharvaris (PHVS) due to positive Phase 3 data for deucrictibant, showing an 83% reduction in HAE attacks. The firm sees potential in treating acquired angioedema and expects FDA approval by April 2027. PHVS shares are down 19% since September 2026, trading at $30.49 with a $2.14B market cap. Analysts project significant upside, with price targets ranging from $41 to $79.

investing.com2 min